best available therapy
Ruxolitinib (RUX) has been shown to significantly reduce spleen volume and risk of death compared with the best available therapy (BAT) in PMF treatment.
Ruxolitinib ( RUX ) has been shown to significantly reduce spleen volume and risk of death compared with the best available therapy ( BAT ) in PMF treatment .